Chardan Capital Has Lowered Expectations for SAB Biotherapeutics (NASDAQ:SABS) Stock Price

SAB Biotherapeutics (NASDAQ:SABS) had its price target reduced by stock analysts at Chardan Capital from $25.00 to $20.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.40.

SAB Biotherapeutics Trading Down 5.7 %

SABS opened at $1.40 on Tuesday. SAB Biotherapeutics has a 12 month low of $1.36 and a 12 month high of $5.01. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.83.

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $43,000. Kovitz Investment Group Partners LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter worth approximately $52,000. Diadema Partners LP purchased a new position in SAB Biotherapeutics during the fourth quarter valued at approximately $114,000. Geode Capital Management LLC boosted its position in shares of SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after purchasing an additional 12,692 shares during the period. Finally, HB Wealth Management LLC increased its stake in shares of SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after purchasing an additional 128,800 shares in the last quarter. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.